Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 16;9(12):1489.
doi: 10.3390/vaccines9121489.

Effectiveness of the WHO-Authorized COVID-19 Vaccines: A Rapid Review of Global Reports till 30 June 2021

Chang-Jie Cheng  1   2 , Chun-Yi Lu  3   4 , Ya-Hui Chang  5 , Yu Sun  1   2 , Hai-Jui Chu  1   2 , Chun-Yu Lee  1   2 , Chang-Hsiu Liu  1 , Cheng-Huai Lin  1 , Chien-Jung Lu  1   2 , Chung-Yi Li  5   6   7
Affiliations
Review

Effectiveness of the WHO-Authorized COVID-19 Vaccines: A Rapid Review of Global Reports till 30 June 2021

Chang-Jie Cheng et al. Vaccines (Basel). .

Abstract

Large clinical trials have proven the efficacy of the COVID-19 vaccine, and the number of studies about the effectiveness rapidly grew in the first half of the year after mass vaccination was administrated globally. This rapid review aims to provide evidence syntheses as a means to complement the current evidence on the vaccine effectiveness (VE) against various outcomes in real-world settings. Databases (PubMed, EMBASE, and MedRxiv) were searched up to 30 June 2021, (PROSPERO ID: 266866). A total of 39 studies were included, covering over 15 million participants from 11 nations. Among the general population being fully vaccinated, the VE against symptomatic SARS-CoV-2 infection was estimated at 89-97%, 92% (95% CI, 78-97%), and 94% (95% CI, 86-97%) for BNT162b2, ChAdOx1, and mRNA-1273, respectively. As for the protective effects against B.1.617.2-related symptomatic infection, the VE was 88% (95% CI, 85.3-90.1%) by BNT162b2 and 67.0% (95% CI, 61.3-71.8%) by ChAdOx1 after full vaccination. This review revealed a consistently high effectiveness of certain vaccines among the general population in real-world settings. However, scarce data on the major variants of SARS-CoV-2 and the shortness of the study time may limit the conclusions to the mRNA vaccines and ChAdOx1.

Keywords: COVID-19; COVID-19 vaccines; SARS-CoV-2 variants.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart of the literature searches.
Figure 2
Figure 2
Vaccine effectiveness against overall SARS-CoV-2 infection.
Figure 3
Figure 3
Vaccine effectiveness against various outcomes. (A) Vaccine effectiveness against asymptomatic infection. (B) Vaccine effectiveness against symptomatic infection. (C) Vaccine effectiveness against hospitalization. (D) Vaccine effectiveness against death. Abbreviations: RLCF: residents of long-term care facilities, SCC: subjects with comorbidity or chronic illness, 65PHC: individuals 65 years and older living at home but requiring practical help and personal care.
Figure 4
Figure 4
Vaccine effectiveness against SARS-CoV-2 variants of concern.
See this image and copyright information in PMC

References

    1. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and efficacy of the chadox1 nCoV-19 vaccine (azd1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. - DOI - PMC - PubMed
    1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Al Kaabi N., Zhang Y., Xia S., Yang Y., Al Qahtani M.M., Abdulrazzaq N., Al Nusair M., Hassany M., Jawad J.S., Abdalla J., et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: A randomized clinical trial. JAMA. 2021;326:35–45. doi: 10.1001/jama.2021.8565. - DOI - PMC - PubMed
    1. Tanriover M.D., Doğanay H.L., Akova M., Güner H.R., Azap A., Akhan S., Köse Ş., Erdinç F., Akalın E.H., Tabak Ö.F., et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (coronavac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in turkey. Lancet. 2021;398:213–222. doi: 10.1016/S0140-6736(21)01429-X. - DOI - PMC - PubMed